Search Results

You are looking at 1 - 10 of 249 items for :

  • "steatosis" x
Clear All
Free access

Irene Andrés-Blasco, Andrea Herrero-Cervera, Ángela Vinué, Sergio Martínez-Hervás, Laura Piqueras, María Jesús Sanz, Deborah Jane Burks and Herminia González-Navarro

. Hypertriglyceridemia and high levels of non-esterified fatty acids (NEFA) in the MetS promote abnormal accumulation of lipids within the liver, in a form of steatosis or non-alcoholic fatty liver disease (NAFLD) ( Bugianesi et al . 2005 ). Thus, NAFLD affects up to 90

Restricted access

Mingjuan Deng, Fang Qu, Long Chen, Chang Liu, Ming Zhang, Fazheng Ren, Huiyuan Guo, Hao Zhang, Shaoyang Ge, Chaodong Wu and Liang Zhao

Introduction Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis and progresses to nonalcoholic steatohepatitis (NASH) that is featured by overt hepatic inflammatory damage ( Sanyal 2005 , Chalasani et al . 2018

Free access

Jie Wei, Xia Sun, Yajie Chen, Yuanyuan Li, Liqiong Song, Zhao Zhou, Bing Xu, Yi Lin and Shunqing Xu

inhalation of low levels of ambient air particulate matter (PM 2.5) has been was reported to induce hepatic steatosis and lipid peroxidation and, moreover, increase hepatic inflammatory and fibrosis stage in mice ( Tomaru et al . 2007 , Tan et al . 2009

Free access

Xuemei Tang, Jingwen Li, Wei Xiang, Ye Cui, Bin Xie, Xiaodong Wang, Zihui Xu and Lixia Gan

with the chow diet mice ( Fig. 5A1 ), and metformin treatment reduced hepatic steatosis ( Fig. 5A4 and A6 ). In consistence, hepatic TG ( Fig. 5B ) are increased by HF, levels of which are significantly decreased after metformin treatment and with a

Restricted access

Lei Yu, Haoran Wang, Xiaoxue Han, Honghui Liu, Dalong Zhu, Wenhuan Feng, Jinhui Wu and Yan Bi

, Pais et al. 2016 ). The global average prevalence of NAFLD in adults is 25%, and 15% of these patients might progress from simple steatosis to non-alcoholic steatohepatitis (NASH), increasing the risk of cirrhosis and hepatocellular carcinoma

Restricted access

Ya Liu, Xiaoqing Zhou, Ye Xiao, Changjun Li, Yan Huang, Qi Guo, Tian Su, Lei Fu and Liping Luo

Introduction Nonalcoholic fatty liver disease (NAFLD), characterized mainly by hepatic steatosis, is the most common liver disease worldwide ( Birkenfeld & Shulman 2014 , Meex & Watt 2017 ). It is reported that NAFLD is closely associated

Free access

Jenny D Y Chow, Margaret E E Jones, Katja Prelle, Evan R Simpson and Wah Chin Boon

Introduction Non-alcoholic fatty liver disease (NAFLD) describes a spectrum of progressive liver abnormalities, ranging from benign hepatic steatosis to the more severe non-alcoholic steatohepatitis (NASH) and cirrhosis ( Adams & Angulo 2006

Free access

Abigail Wolf Greenstein, Neena Majumdar, Peng Yang, Papasani V Subbaiah, Rhonda D Kineman and Jose Cordoba-Chacon

Introduction Non-alcoholic fatty liver disease (NAFLD) is defined as excessive accumulation of fat (steatosis) within hepatocytes that is independent of alcohol intake. NAFLD increases the risk of diabetes, non-alcoholic steatohepatitis (NASH

Free access

Raquel Barbuio, Marciane Milanski, Manoel B Bertolo, Mário J Saad and Lício A Velloso

Introduction Non-alcoholic fatty liver disease (NAFLD) comprehends a large spectrum of clinicopathological conditions of the liver, ranging from steatosis to cirrhosis, and including steatohepatitis (NASH) and fibrosis ( Browning

Free access

Jin-Bong Lee, Sung-Jin Yoon, Sang-Hyun Lee, Moo-Seung Lee, Haiyoung Jung, Tae-Don Kim, Suk Ran Yoon, Inpyo Choi, Ik-Soo Kim, Su Wol Chung, Hee Gu Lee, Jeong-Ki Min and Young-Jun Park

. 2017 ). In our study, we found that Rg3 improved insulin sensitivity and ameliorated hepatic steatosis in the mouse model and reduced lipid accumulation in the cell culture model, acting though as the STAT5-PPAR axis. Based on the results, we suggest